Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Estrella Immunopharma ( (ESLA) ) just unveiled an update.
Estrella Immunopharma, Inc. has appointed Dr. Cheng Liu as Director, President, and CEO with an ‘at will’ employment agreement offering a $250,000 annual salary, bonus potential, and equity incentives. The contract allows flexibility for termination and offers severance packages based on the circumstances, highlighting the company’s strategic focus on aligning leadership performance with financial and operational goals.
Find detailed analytics on ESLA stock on TipRanks’ Stock Analysis page.